Savvy pharma-stock investors know that an oral GLP-1 drug from Novo Nordisk called Rybelsus has been on the market as a ...

Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily ...

The results Lilly is reporting for its oral pill come as another big drug company, Pfizer, has decided to discontinue its ...

Eli Lilly said in February that it will invest at least $27 billion to build four new manufacturing sites in the U.S. as ...

Eli Lilly is getting closer to bringing a weight loss pill to market, but CEO David Ricks notes certain factors need to be considered to prevent prices from ballooning.

In a new First Opinion essay, Borio and Krause, both once top FDA officials, say the commissioner made a “rookie misstep” in ...

Eli Lilly (NYSE: LLY) stock jumped over 14% on Thursday, powered by highly promising Phase 3 results for orforglipron, an ...

What a difference five years can make. Just look at Eli Lilly (NYSE: LLY). In April 2020, the drugmaker stood in the shadows ...

The drug helped lower patients’ blood sugar and reduce their weight by an average of 16 pounds.

The results bring Eli Lilly's pill orforglipron one step closer to becoming a new, needle-free alternative in the booming ...

Eli Lilly has met its goal of achieving semaglutide-like efficacy with an oral GLP-1 drug. | Eli Lilly has met its goal of ...

U.S. Trade Representative Jamieson Greer said the Trump Administration excluded pharmaceuticals and semiconductors from reciprocal tariffs ...